News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


PHARMAC decision impacts heavily

Chief Reporter Scoop


** PHARMAC decision impacts heavily **

A good quality of life for older people with Alzheimer' disease is being denied by PHARMAC's refusal to subsidise new medications. Cost savings in residential and hospital care that could result appear to have been ignored.

"Having recently attended the Alzheimer's Disease International conference, our eyes have been opened to the level of help and relief that is available to many people, through the use of a managed care programme with Alzheimer's medications," says Garth Taylor, Chief Executive, Age Concern New Zealand.

PHARMAC NZ has given a low priority rating to subsidise medications that have been proven to help Alzheimer's' sufferers in a significant number of cases. As the condition progresses, residential and hospital care become inevitable. Any delay in admission to care facilities would result in significant cost savings to the Government and taxpayers.

"This response effectively denies treatment to thousands of New Zealanders with this condition," says Mr Taylor. "What is particularly distressing is that New Zealand stands out as one of a few developed countries where Alzheimer's drugs are not reimbursed by the Government or private health plans. Our 'cousins' in Australia and the UK are able to access them freely, and one must question why PHARMAC chooses to ignore evidence that other countries pharmaceutical agencies have accepted. Is it a case of ignoring the rights of the older members of our community?

"As an advocate for older people, Age Concern is particularly disturbed that many New Zealanders will be denied their dignity and will suffer as a consequence of this decision. It not only affects the sufferer but also their carer and family. It seems that if you are well off and can afford to pay for these medications then you are able to access treatment, but for the ordinary New Zealander this is denied because of the cost.

"We are concerned this PHARMAC decision is indicative of a much wider issue - that there appears to be no provision for the funding of new and progressive drugs that may become available to treat conditions that mainly affect the older population."


For further information please contact:

Garth Taylor, Chief Executive (wk) 0-4-471 2709 or (mobile) 025 243 6991

© Scoop Media

Culture Headlines | Health Headlines | Education Headlines

Legendary Bassist David Friesen Plays Wellington’s Newest Jazz Venue

Friesen is touring New Zealand to promote his latest album Another Time, Another Place, recorded live at Auckland's Creative Jazz Club in 2015. More>>

Howard Davis Review: The Father - Descending Into The Depths of Dementia

Florian Zeller's dazzling drama The Father explores the effects of a deeply unsettling illness that affects 62,000 Kiwis, a number expected to grow to 102,000 by 2030. More>>

Howard Davis Review: Blade Runner Redivivus

When Ridley Scott's innovative, neo-noir, sci-fi flick Blade Runner was originally released in 1982, at a cost of over $45 million, it was a commercial bomb. More>>

14-21 October: New Zealand Improv Festival In Wellington

Imagined curses, Shibuya’s traffic, the apocalypse, and motherhood have little in common, but all these and more serve as inspiration for the eclectic improvised offerings coming to BATS Theatre this October for the annual New Zealand Improv Festival. More>>


Bird Of The Year Off To A Flying Start

The competition asks New Zealanders to vote for their favourite bird in the hopes of raising awareness of the threats they face. More>>

Scoop Review Of Books:
K Emma Ng's Old Asian, New Asian

This book, written by a young second-generation Chinese New Zealander, gives many examples of the racism that Asian New Zealanders experience. More>>